Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma

被引：0

作者：

Xiaoying Gu

Su Zhang

Xuejiao Yang

Tao Guan

Zhenyu Hou

Manqing Cao

Huikai Li

Ti Zhang

机构：

[1] Tianjin Medical University Cancer Institute and Hospital,Department of Hepatobiliary Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy

[2] National Clinical Research Center for Cancer,Department of Gynecologic Oncology, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy

[3] Tianjin Medical University Cancer Institute and Hospital,Present Address: Department of Anesthesiology

[4] National Clinical Research Center for Cancer,Department of Breast Surgery, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy

[5] The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture,Present Address: Department of Hepatic Surgery

[6] Tianjin Medical University Cancer Institute and Hospital,undefined

[7] National Clinical Research Center for Cancer,undefined

[8] Fudan University Shanghai Cancer Center,undefined

[9] Shanghai Medical College,undefined

[10] Fudan University,undefined

来源：

BMC Gastroenterology | / 22卷

关键词：

Apatinib; Anti-angiogenesis therapy; Adverse Events; Hepatocellular Carcinoma; Prognosis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Adverse Events in Targeted Therapy for Unresectable Hepatocellular Carcinoma Predict Clinical Outcomes
Imai, Kenji
Takai, Koji
Aiba, Masashi
Unome, Shinji
Miwa, Takao
Hanai, Tatsunori
Suetsugu, Atsushi
Shimizu, Masahito
CANCERS, 2024, 16 (18)
[42] Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib plus chemotherapy: Results from two prospective studies
Lin, R.
Zhao, S.
Su, L.
ANNALS OF ONCOLOGY, 2023, 34 : S1549 - S1549
[43] Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma.
Hoshida, Y
Shiratori, Y
Koike, Y
Obi, S
Hamamura, K
Teratani, T
Shiina, S
Omata, M
HEPATOLOGY, 2000, 32 (04) : 238A - 238A
[44] Reducing Drug-related Allergic Events
McGregor, C. A.
Smith, S.
Finlay, S.
SCOTTISH MEDICAL JOURNAL, 2010, 55 (03) : 54 - 54
[45] Association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the Phase III CELESTIAL trial
Strasser, S.
Abou-Alfa, G.
Meyer, T.
Cheng, A.
Cicin, I.
Bolondi, L.
Klumpen, H.
Chan, S.
Zagonel, V.
Milwee, S.
Dubey, S.
Kelley, R.
El-Khoueiry, A.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 33 - 34
[46] The efficacy and adverse effects of nivolumab and lenvatinib in the treatment of advanced hepatocellular carcinoma
Wen, Shilai
Zeng, Jingke
Zhong, Liting
Ye, Jianmin
Lai, Xiaohuan
CELLULAR AND MOLECULAR BIOLOGY, 2022, 68 (11) : 53 - 57
[47] Can social media data lead to earlier detection of drug-related adverse events?
Duh, Mei Sheng
Cremieux, Pierre
Van Audenrode, Marc
Vekeman, Francis
Karner, Paul
Zhang, Haimin
Greenberg, Paul
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (12) : 1425 - 1433
[48] Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
Majid Jaberi-Douraki
Xuan Xu
Danai Dima
Sikander Ailawadhi
Faiz Anwer
Sandra Mazzoni
Jason Valent
Muhammad Hamza Habib
Jim E. Riviere
Shahzad Raza
Blood Cancer Journal, 14 (1)
[49] Elderly Patients with Advanced Hepatocellular Carcinoma Could be Effectively Treated without Age-Related Adverse Events
Torimura, Takuji
Niizeki, Takashi
Nakano, Masahito
Shimose, Shigeo
Shirono, Tomotake
Iwamoto, Hideki
Koga, Hironori
HEPATOLOGY, 2018, 68 : 848A - 849A
[50] Adverse events of immune checkpoint inhibitors in advanced hepatocellular carcinoma and their prognostic significance
Wilhelmi, Markus
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (04) : 483 - 483

← 1 2 3 4 5 →